Japanese
Translation
|
Endometriosis in adolescents
(supporting documentation)
Symptoms
| B |
It is hard to
predict the presence of endometriosis in adolescents with pelvic
pain merely from the presenting symptoms, because similar symptoms
occur in patients evaluated laparoscopically for pelvic pain with
and without endometriosis ( Reese
et al., 1996; Laufer
et al., 1997). |
Evidence Level 3 |
Endometriosis can be confirmed
by laparoscopy in adolescents under evaluation for chronic pelvic pain.
The most common presenting symptom in adolescents with endometriosis
is cyclic pain. Less commonly acyclic pain, dyspareunia, gastrointestinal
symptoms, irregular menses, urinary symptoms and vaginal discharge are
described (Goldstein et al.,
1980; Bai et al., 2002;
Ballweg, 2003). However,
similar presenting symptoms occur in adolescent patients evaluated for
pelvic pain with and without endometriosis (Reese
et al., 1996; Laufer et
al., 1997).
Laparoscopic evaluation of
chronic pelvic pain
| B |
Laparoscopy should
be considered if adolescents with chronic pelvic pain who do not
respond to medical treatment (NSAIDs, OCPs) since endometriosis
is very common under these circumstances ( Goldstein
et al., 1980; Vercellini
et al., 1989; Reese et
al, 1996; Laufer et
al., 1997; Emmert et
al., 1998; Hassan et
al., 1999; Kontoravdis
et al., 1999; Shin et
al., 2005; Stavroulis
et al., 2006). |
Evidence Level 3 |
Endometriosis lesions can be detected
frequently in adolescent patients with chronic pelvic pain. Prevalence
rates of endometriosis in adolescent patients undergoing laparoscopy
for chronic pelvic pain range from 19% to 73% (Goldstein
et al., 1980; Vercellini
et al., 1989; Reese et al,
1996; Laufer et al., 1997;
Emmert et al., 1998; Hassan
et al., 1999; Kontoravdis
et al., 1999; Shin et al.,
2005). Because dysmenorrhoea is very common in adolescents not all
young women with pelvic pain can be subjected to invasive diagnosis
by laparoscopy. However, if combination hormone therapy (such as oral
contraceptive pills) or non-steroidal anti-inflammatory drugs fail,
35-73% of adolescents do have endometriosis at the time of laparoscopy
(Reese et al, 1996; Laufer
et al., 1997; Stavroulis
et al., 2006).
Extent and appearance of the
disease
| B |
Minimal to mild
endometriosis according to the rASRM classification are the most
common stages of the disease in adolescents. Gynaecologic surgeons
should pay special attention to red, clear or white lesions which
were reported to be more prevalent in adolescents as opposed to
adults who have endometriosis ( Goldstein
et al., 1980; Vercellini
et al., 1989; Davis et
al., 1993; Reese et al,
1996; Laufer et al.,
1997; Emmert et al.,
1998; Hassan et al.,
1999; Bai et al., 2002;
Marsh and Laufer, 2005). |
Evidence
Level 3 |
Obstructive genital anomalies
| B |
Menstrual outflow
obstructions such as Müllerian anomalies may cause early development
of endometriosis in adolescents. Regression of the disease has been
observed once surgical correction of the anomaly has been accomplished
( Sanfilippo et al.,
1986; Ugur et al., 1995;
Hur et al., 2007). |
Evidence
Level 3 |
Similar prevalence rates of endometriosis
were reported in a group of 186 patients with Müllerian anomalies
compared to controls without Müllerian anomalies (19.8 % vs. 19.1
%). However, if patients without functioning endometrium were excluded,
endometriosis was found significantly more common in patients with outflow
obstruction (57.6 %) compared to patients with non-obstructive type
of anomaly (17.6 %) (Ugur et al.,
1995).
Treatment
| GPP |
Physicians treating
adolescents with endometriosis should adopt a multidimensional approach:
Surgery, hormonal manipulation, pain medication, mental health support,
complementary and alternative therapies, and education in self management
strategies are useful components. |
Treatment algorithms for management of
adolescent endometriosis are based upon pathophysiologic principles
and extrapolation of data from adult endometriosis. A small case series
of 11 laparoscopically and hormonally treated adolescent patients reported
excellent responses even in patients with severe endometriosis (Stavroulis
et al., 2006). A literature review on the impact of gonadotropin-releasing
hormone agonists on bone mass in adolescents not responding to conventional
therapy could not identify any study specifically studying the adolescent
population. Thus, the ideal dosage and long-term effects of add-back
therapy remains to be determined (Lubianca
et al., 1998).
Concise
|
|
|